MK-6024_PBO_0.5mL clinical trials

A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis

This study is looking at a new medicine called efinopegdutide for adults with a liver condition called non-alcoholic steatohepatitis (NASH). It compares this new medicine with another one called semaglutide or a dummy treatment to see if it improves the liver and is safe.